We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




POC Hemometer Compared with Hematology Analyzer

By LabMedica International staff writers
Posted on 18 Apr 2019
The burden of anemia remains unacceptably high in sub-Saharan Africa. More...
It is linked to numerous life-threatening consequences like poor cognitive ability, diminished immunity and aggravated mortality.

To avert its effect, timely and accurate determination of hemoglobin concentration has been recognized. This has taken varied determination methods such as cyanmethemoglobin, use of copper II sulfate, automated hematology analyzers and point-of-care (POC) devices as the latest invention.

Medial Laboratory Scientists at Clarke International University (Kampala, Uganda) and their colleagues enrolled 402 participants, of these, 156 (38.8%) were male and 246 (61.2%) female. Participants had varied age categories, of whom 65 (16.2%) were 1 month–5 years, 42 (10.4%) were 5–11 years, 12 (3.0%) were 12–14 years, while 283 (70.4%) were 15 years and older. The average levels of Hb were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic participants, respectively.

Blood samples were assayed to estimate the hemoglobin (Hb) concentration using the TrueHb hemometer and Sysmex i3 hematology analyzer. Anemia was defined as Hb levels less than 11.0 g/dL, 11.5 g/dL and 12.0 g/dL for children aged 6–59 months, 5–11 years and 12–14 years, respectively. For adults, anemia was considered as Hb concentration less than 12.0 g/dL in non-pregnant women, 11.0 g/dL in pregnant women and 13.0 g/dL in males.

The team reported that the average Hb levels were 8.7 ± 1.8 and 13.3 ± 2.6 g/dL for the anemic and non-anemic patients, respectively. They found that 155 participants were anemic, giving an anemia prevalence of 38.6%. The mean difference of the TrueHb and Sysmex i3 assays was 2.222 ± 1.079, and the two devices did not show a difference in their measurements. Further, they showed a significant level of agreement and intraclass correlation coefficients. The sensitivity, specificity, positive and negative predictive values were 100 %, 51.01%, 55.16% and 100 %, respectively. The average performance turnaround time (TAT) for the TrueHb hemometer was 2.46 minutes.

The authors concluded that the TrueHb POC hemometer is an accurate POC for Hb estimation with a good performance agreement with the Sysmex i3 analyzer. This, coupled with its utility aspects, makes it a good diagnostic tool in a high anemia burden and low-resource setting. The study was published on April 1, 2019, in the Journal of Blood Medicine.

Related Links:
Clarke International University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated Urinalysis Solution
UN-9000
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.